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In Brief
ERRa is the oldest orphan nuclear receptor. Combining affinity chromatography with tissue lipidomics, Wei et al. identify cholesterol as an endogenous ERRa agonist. ERRa mediates the effects of cholesterol on osteoclasts, macrophages, and myocytes, as well as the pharmacological effects of statins and bisphosphonates on bone resorption and skeletal remodeling.
INTRODUCTION
Estrogen-related receptors (ERRs) are a family of nuclear receptors that consist of ERRa, ERRb, and ERRg (Giguè re, 2002; Giguè re et al., 1988) . ERRs control pathophysiological processes, such as cancer and skeletal homeostasis, by regulating the expression of specific target genes. ERRa is the most-studied member of this subgroup and an orphan receptor because it lacks an endogenous (or natural) ligand. The identification of an endogenous nuclear receptor ligand is crucial to understand how the receptor is regulated. This information is of fundamental biological interest. Moreover, if the nuclear receptor is involved in diseases, knowledge on how to manipulate the levels of a ligand can be used to develop novel therapeutics. For instance, knowing that estrogen, a product of the aromatase enzyme, activates the estrogen receptor a (ERa), a nuclear receptor, led to the development of aromatase inhibitors to treat ERa-driven cancer by inhibiting estrogen production (Johnston and Dowsett, 2003) .
ERRa was originally identified based on its homology to ERa (Giguè re et al., 1988) . Analysis of the individual domains reveals that the DNA-binding domains (DBDs) of ERRa and ERa are 70% homologous, but their ligand-binding domains (LBDs) are only 36% similar, explaining why ERa ligands do not activate ERRa. 17b-estradiol, estrone, and estriol are all ERa regulators (Ascenzi et al., 2006) , but these steroid hormones have no effect on ERRa function (Horard and Vanacker, 2003) . The absence of an endogenous or dietary lipid ligand for ERRa has led to the hypothesis that ERRa is a ligand-less receptor (Kallen et al., 2004) . This idea is bolstered by constitutive activity of the ERRa in the absence of an added ligand and structural biology that revealed that the ERRa ligand-binding pocket is almost completely occluded.
ERRa modulates energy metabolism (Giguè re, 2008; Luo et al., 2003) ; ERRa deletion or inhibition confers resistance to obesity and insulin resistance (Luo et al., 2003; Patch et al., 2011; Sladek et al., 1997) . ERRa also regulates skeletal remodeling by controlling osteoclastogenesis, a key cellular differentiation process essential for bone resorption (Gallet and Vanacker, 2010; Wan, 2010; Wei et al., 2010) ; ERRa deletion impairs osteoclast differentiation and bone resorption, leading to increased bone mass (Wei et al., 2010) . Furthermore, ERRa is also a critical regulator of multiple cancers (Stein and McDonnell, 2006; Suzuki et al., 2004) .
The importance of ERRa in human health has led to tremendous interest in this protein as a novel therapeutic target. A number of synthetic small-molecule ERRa antagonists have been developed. These compounds bind to the ERRa ligand-binding domain (LBD) and induce a conformational shift in the ERRa-LBD that interferes with coactivator binding to inhibit transcription. ERRa antagonists have been found to induce cancer cell death (Wu et al., 2009) , inhibit tumor growth (Duellman et al., 2010) , and improve insulin sensitivity and glucose tolerance (Patch et al., 2011) . More generally, the discovery of these antagonists indicates that ERRa has a functional small-molecule binding pocket, renewing the idea that ERRa has an endogenous ligand.
The identification of endogenous nuclear receptor ligands is typically accomplished using functional screens to find metabolites that regulate nuclear receptor transcriptional activity. While successful, cell-based assays with natural metabolites have certain drawbacks that could potentially lead to false negatives. Recent work, for example, has demonstrated the importance of cellular proteins in the transport (Ayers et al., 2007) and metabolism (Chakravarthy et al., 2009 ) of endogenous ligands. To obviate the need to consider these variables, we decided on using a lipidomic strategy to identify candidate endogenous ligand(s) for ERRa.
RESULTS
Cholesterol Enrichment and Binding to the ERRa LBD We used an affinity chromatography approach to determine whether the ERRa-LBD binds to any endogenous lipids (Figure 1A) . This method was previously used to enrich known endogenous PPARg ligands from the lipidome , validating the compatibility of this approach with nuclear receptors. Recombinant N-terminal 6xHis-tagged ERRa-LBD was expressed, purified, and immobilized onto IMAC Sepharose 6 Fast Flow beads (resin). Lipidomes were prepared for affinity chromatography by extracting mouse brain with chloroform/ methanol/water, isolating the organic fraction, and concentrating this fraction containing all lipids. Brain was selected because of the robust expression of ERRa (Bookout et al., 2006) . The lipids were then dissolved in DMSO and mixed with buffer to afford a lipidome sample that is compatible with affinity chromatography. Resin loaded with ERRa-LBD was incubated with the lipidome. After incubation, the buffer was filtered away from the resin, and the resin was washed with buffer to remove weak interactions. The 6xHis-tagged ERRa-LBD is then eluted from the beads through the addition of buffer containing imidazole. Performing the exact steps with IMAC Sepharose 6 Fast Flow beads lacking any protein afforded the control sample for these experiments.
The ERRa-LBD sample and the control sample were analyzed by untargeted liquid chromatography-mass spectrometry lipidomics. These lipidomics data sets were then compared using the XCMS software package (Smith et al., 2006) , which quantifies the levels of metabolites in two samples to reveal any differences in lipid concentrations. XCMS identified a single ion that was significantly enriched by the beads bound to ERRa-LBD (p < 0.05 and >2-fold), and this ion belongs to cholesterol ( Figure 1B ). These data indicate that the ERRa-LBD binds cholesterol. We have previously performed this affinity chromatography experiment with three different proteins (FABP, CRABP, StarD3) Table S1 . (Tagore et al., 2008) and three different nuclear receptors (PPARg, PPARa, and Nurr77) Vinayavekhin and Saghatelian, 2011) . StarD3, a known cholesterol-binding protein, was the only one of these proteins or nuclear receptors to enrich cholesterol, demonstrating that this experiment is not biased toward cholesterol enrichment to support a specific interaction between ERRa-LBD and cholesterol. We wanted to test the specificity of the ERRa-cholesterol interaction by repeating the affinity chromatography with tissue sterols. This required fractionation of the sterols away from other lipids using a validated method (McDonald et al., 2007) . This sterol fraction from brain or kidney was then used for affinity chromatography with resin loaded with ERRa-LBD as described above. In addition, we used a targeted LC-MS method that is specific for sterols (i.e., cholesterol, oxysterols, etc.) (McDonald et al., 2007) to increase our detection sensitivity for lower abundance sterols. We measured 19 different sterols with this approach and only detected the enrichment of cholesterol (4.6-and 6.7-fold for the brain and kidney samples, respectively) ( Table S1 ). These data are consistent with the lipidomics experiment. Next we performed a competitive binding assay with diethylstilbestrol (DES), a synthetic ERRa antagonist that binds to the ERRa lipid-binding pocket (Tremblay et al., 2001) , to test the specificity of the cholesterol interaction with the ERRa-LBD. DES was added to the brain lipidome before affinity chromatography with the ERRa-LBD beads. DES prevented enrichment of cholesterol (Figure 1D ) by binding to the ERRa-LBD ( Figure S1B ), which indicates that cholesterol binds to the ERRa-LBD lipid-binding pocket.
To complement these affinity chromatography experiments, we further characterized the biochemical interaction between cholesterol and ERRa-LBD using several secondary assays. First, circular dichroism (CD) spectroscopy showed that cholesterol, as well as synthetic ERRa antagonists DES and XCT790, all induced conformational changes in ERRa-LBD, whereas estradiol, which does not bind to ERRa-LBD, did not ( Figure S2 ). This change in conformation implies that all of these molecules can bind to the ERRa-LBD, and the fact that estradiol, a lipid with similar biophysical properties, does not cause a change supports that this binding is more than a simple hydrophobic interaction.
Second, computational docking of cholesterol into the ERRa ligand-binding pocket suggested that cholesterol bound with its hydroxyl group facing into the ligand-binding pocket (Figure 2A) . We tested this model using a fluorescence polarization experiment with dye-labeled cholesterol derivatives and sitedirected mutagenesis. Fluorescence polarization indicated that 25-[N-[(7-nitro-2-1,3-benzoxadiazol-4-yl)methyl]amino]-27-norcholesterol (25-NBD-cholesterol), a cholesterol derivative with a dye extending from carbon 25 of the norcholesterol, bound ERRa-LBD with a dissociation constant of 9 mM. According to the structural model (Figure 2A ), carbon 25 is outside of the ERRa-LBD lipid-binding pocket and therefore should not interfere with binding, which is what we observed. By contrast, 6-NBD-cholesterol, which would place the NBD directly inside the binding pocket, did not bind the ERRa-LBD at all ( Figure 2B ). Furthermore, cholesterol, but not estradiol, was able to compete with 25-NBD-cholesterol for binding to ERRa-LBD ( Figure 2C ). Third, to ensure that the NBD is not contributing to the binding, we performed a tryptophan fluorescence spectroscopy assay with cholesterol. In this experiment, binding of cholesterol to the ERRa-LBD quenches intrinsic tryptophan fluorescence of the ERRa-LBD, to afford a label-free method for testing binding. In contrast, estradiol did not quench the intrinsic tryptophan fluorescence of ERRa-LBD ( Figure 2D) . Lastly, the model predicts a hydrogen bond between E235 and the cholesterol hydroxyl group, and F232 and L228 also appear to make important hydrophobic contacts with cholesterol (Figure 2A) . Site-directed mutagenesis of ERRa-LBD at E235A, F232A, and L228A generated a mutant ERRa-LBD that appeared folded properly by CD ( Figure S3 ), but displayed a greatly reduced cholesterol binding ( Figure 2E ), indicating that disruption of the lipid-binding pocket interferes with cholesterol binding. Together, these experiments provide strong evidence of cholesterol binding to the ERRa-LBD, but do not indicate whether this binding is functional.
Cholesterol Increases ERRa Transcriptional Activity
To determine whether cholesterol is a functional endogenous ERRa ligand in cells, we next examined the impact of modulating the cholesterol biosynthetic pathways on ERRa transcriptional activity. Conventional luciferase transactivation strategies, where a ligand is added to detect an increase in transcriptional activity, are complicated by the presence of abundant cholesterol in the media and cells. Rather than introducing cholesterol, we decided that a more prudent strategy would be to measure ERRa activity upon sterol depletion. We lowered intracellular sterol levels in three ways: the use of lipid-free serum, the addition of the cholesterol-binding hydoxypropyl cyclodextrin (HPCD), and the addition of the lovastatin. The individual addition of HPCD or statin was able to attenuate ERRa transactivation ( Figure 3A ), indicating that sterol levels positively correlate with ERRa activity, as expected for an agonistic metabolic pathway that activates ERRa. Moreover, when combined, these compounds also had an additive effect on the lowering of ERRa activity ( Figure 3A ). Importantly, adding back cholesterol to these HPCD-and statin-treated samples rescued ERRa activity in a dose-dependent manner, indicating that cholesterol or a downstream sterol, but not a precursor of the cholesterol pathway, is involved in ERRa activity ( Figure 3B ). As a positive control, the synthetic ERRa antagonist/inverse agonist XCT790 further decreased ERRa transactivation ( Figure 3B ). As negative controls, these effects were not observed for ERRb, ERRg, or other orphan nuclear receptors such as Nur77 ( Figure S4 ). Importantly, the effects of cholesterol depletion and cholesterol add-back on ERRa activation of transcription were only observed in the presence of ERRa coactivators such as PGC1a ( Figures 3A and 3B) ; in the absence of PGC1a, neither ERRa nor cholesterol could enhance the transcription (data not shown), indicating that cholesterol activation of ERRa function is PGC1a dependent. These results suggest that cholesterol is a functional ERRa agonist.
ERRa Mediates Statin-Induced Muscle Toxicity
On the basis of these findings, we investigated whether the cholesterol pathway and ERRa are functionally dependent. We examined skeletal muscle, a well-known ERRa-regulated tissue.
Statins are the most efficient drugs for the treatment of hypercholesterolemia that is generally considered safe and well tolerated. However, the most severe adverse effect of statins is myotoxicity, for which there is still no clear pathophysiology or effective treatment (Echaniz-Laguna et al., 2010; Sathasivam, 2012; Tomaszewski et al., 2011) . It has been reported that statins induce myopathy by inhibiting myotube differentiation and inducing the expression of the muscle atrophy gene atrogin-1 (Fbxo32) (Hanai et al., 2007) . Thus, we examined whether the effects of statin on muscle are ERRa dependent in vitro and in vivo. Treatment of C2C12 myotube differentiation cultures with either lovastatin or simvastatin significantly suppressed myotube formation, decreased the expression of myotube markers, and increased the expression of Fbxo32 ( Figures 4A-4C ). Treatment with the ERRa antagonist XCT790 exhibited similar effects . This indicates that either a reduction of endogenous ERRa agonists by sterol depletion or an inhibition of ERRa activity by XCT790 leads to myotube defects. The effects of statins were largely rescued by adding back cholesterol to the cultures, but this rescue was absent when ERRa function was blocked by XCT790 ( Figures 4A-4C ), indicating that regulation by cholesterol is ERRa dependent. These observations may extend beyond C2C12 cells, since statin can induce toxicity in many cell types.
We next treated ERRa-KO mice or WT controls with simvastatin (20 mg/kg/day) or vehicle control for 2 weeks. Both simvastatin-treated WT mice and vehicle-treated ERRa-KO mice exhibited myopathy compared with vehicle-treated WT controls, shown by the decreased expression of myotube markers (Figure 4D) and increased expression of Fbxo32 in skeletal muscles ( Figure 4E ), as well as the elevated creatine kinase levels in serum, a biomarker for muscle damage (Echaniz-Laguna et al., 2010) ( Figure 4F ). Importantly, the myopathy-inducing effects of statin were completely abolished in ERRa-KO mice ( Figures  4D-4F ). In line with these observations, ERRa association with its coactivator PGC1a was inhibited by statin, which was partially rescued by cholesterol in C2C12 myotube differentiation cultures ( Figure 4G ), suggesting that cholesterol binding to ERRa causes a conformational change in the LBD and the recruitment of coactivator to enhance ERRa-mediated transcription. Together, these findings indicate that physiological regulation by cholesterol and pharmacological regulation by statins are ERRa dependent, supporting that the cholesterol pathway exerts a functional control of ERRa activity.
ERRa Mediates Cholesterol, Statin, and Bisphosphonate Regulation of Osteoclastogenesis
To further investigate the functional role of cholesterol as an endogenous ERRa ligand, we examined osteoclastogenesis, a cellular differentiation process crucial for the physiological regulation of bone remodeling and skeletal regeneration, which also contributes to diseases such as osteoporosis and cancer bone metastases when overactive. Upon activation by receptor activator of nuclear factor kappa-B ligand (RANKL), osteoclasts are differentiated from monocyte/macrophage precursor cells in the blood circulation and bone marrow (Novack and Teitelbaum, 2008) . We have recently shown that ERRa promotes osteoclast differentiation and activity, and as a result, ERRa knockout mice exhibit decreased bone resorption and high bone mass (Wei et al., 2010) . Interestingly, both statins and nitrogen-containing bisphosphonates suppress osteoclast function; and both inhibit the cholesterol synthesis pathway, by blocking the HMG-CoA reductase and farnesyl diphosphate synthase (FPPS), respectively (Russell, 2011; Toledano and Partridge, 2000) . However, the molecular target for how exactly the cholesterol synthesis pathway impacts osteoclastogenesis is still an open question, although interference with protein prenylation by bisphosphonates has been suggested (Russell, 2011) .
To test the hypothesis that cholesterol, statins, and bisphosphonates regulate osteoclast differentiation via ERRa, we performed ex vivo bone marrow osteoclast differentiation assays. We found that osteoclastogenesis from WT bone marrow cells was dependent on the presence or absence of cholesterol. Cholesterol addition enhanced osteoclast formation, whereas cholesterol depletion by treatment with zoledronate (a clinically used nitrogen-containing bisphosphonates) or lovastatin inhibited osteoclast formation ( Figure 5A ). Cholesterol adding back to zoledronate-or lovastatin-treated cells was able to rescue osteoclast differentiation, indicating cholesterol or a downstream sterol, rather than cholesterol precursors in the biosynthetic pathway, was responsible for the changes in differentiation ( Figure 5A ). Gene expression analysis showed that cholesterol upregulated the expression of both ERRa target genes that stimulate mitochondrial biogenesis and osteoclast activity, such as Aco2, IDH3a, and VLCAD (Wei et al., 2010) , and osteoclast differentiation markers such as TRAP (tartrateresistant acid phosphatase) and Ctsk (Cathepsin K) ( Figure 5B) . Similar experiments using ERRa knockout (ERRaKO) bone marrow osteoclast differentiation cultures reveal that the effects of cholesterol on osteoclastogenesis were completely abolished by ERRa deletion. In the absence of ERRa, osteoclast differentiation was neither enhanced by cholesterol nor suppressed by lovastatin or zoledronate ( Figure 5A ). Consistent with this observation, cholesterol, lovastatin, or zoledronate no longer altered the expression of ERRa target genes or osteoclast differentiation markers ( Figure 5B ). In addition to genetic loss of function by ERRa deletion, biochemical inhibition with a synthetic ERRa antagonist XCT790 also prevented the effects of cholesterol on WT osteoclast differentiation ( Figure 5C ). The suppressive effects of XCT790 on ERRa target genes and osteoclast differentiation makers were absent in ERRaKO cultures, indicating that XCT790 mainly targeted ERRa ( Figure S5A ). These data indicate that cholesterol enhances osteoclastogenesis in an ERRa-dependent manner.
In osteoclasts, PGC1b is the ERRa coactivator, whereas PGC1a is not expressed (Wei et al., 2010) . Once again, ERRa association with PGC1b was inhibited by statin, which was largely rescued by cholesterol add-back in osteoclast differentiation cultures ( Figure 5D ). Expression of ERRa and PGC1 was unaffected by statin or cholesterol under these conditions ( Figures  S5B and S5C ). In conjunction with biochemical data demonstrating cholesterol binding to ERRa LBD and cellular reporter assays demonstrating cholesterol stimulation of ERRa transcriptional activity, these results suggest that cholesterol promotes osteoclastogenesis by functioning as an ERRa agonist, whereas statins and bisphosphonates suppress osteoclastogenesis by reducing the bioavailability of the endogenous ERRa agonist cholesterol.
These clear phenotypic outcomes in cells provided us an opportunity to pin down the altered sterol species that modulate ERRa activity. Specifically, we measured sterol levels under different conditions during osteoclastogenesis using the highly sensitive sterol LC-MS measurements. Any sterol that activates ERRa must (1) have higher levels in cholesterol-treated cells, (2) have lower levels in lovastatin-and zoledronate-treated cells, and (3) have a level rescued back to normal control when cholesterol is added back to lovastatin-and zoledronate-treated cells. Although many sterols were detected and measured, cholesterol was the only sterol fitting all three criteria whose cellular levels correlated with changes in ERRa activity in response to statin and bisphosphonate ( Figure S6 ). In combination with the biochemical characterization of ERRa-LBD as a cholesterolbinding protein, these cellular data support the notion that cholesterol is an endogenous ERRa agonist. Although there may be additional, undetected or unknown, metabolites downstream of cholesterol, these results indicate that cholesterol is the major sterol in the cholesterol pathway that modulates ERRa activity.
ERRa Mediates Cholesterol, Statin, and Bisphosphonate Regulation of Macrophage
To examine the functional association between ERRa and cholesterol in the myeloid lineage under a different biological context, we next investigated whether the recently reported anti-inflammatory role of cholesterol in macrophages was also ERRa dependent. Cholesterol has been shown to inhibit macrophage expression of chemokines Cxcl9 and Cxcl10 (Spann et al., 2012) . We found that the LPS-induced Cxcl9 and Cxcl10 expression was suppressed by cholesterol but exacerbated by lovastatin or zoledronate in WT macrophages ( Figure 5E ). These effects were once again abolished in ERRaKO macrophages ( Figure 5E ). Furthermore, cholesterol inhibition of Cxcl9 and Cxcl10 expression was also absent in WT macrophages treated with XCT790 ( Figure 5F ). Similar regulation was observed for other inflammatory markers such as IL-1b and MMP9 ( Figures  S5D and S5E ). In contrast, cholesterol regulation of SREBP and LXR target genes was intact in ERRaKO macrophages (Figure S5F ). These data not only indicate that the chemokine-suppressive effect of cholesterol in macrophages is ERRa-mediated but also reveal a novel anti-inflammatory role for ERRa in a cholesterol-rich environment. Importantly, these results provide further evidence that cholesterol is a functional ERRa agonist in another biological process.
ERRa Mediates Cholesterol Regulation of Bone Resorption In Vivo
To gain further insight as to whether the functional relationship between cholesterol and ERRa extends to physiology and pharmacology, we next performed in vivo studies in the context of bone resorption and skeletal remodeling. Epidemiological and pharmacological studies in human show that cholesterollowering drugs such as bisphosphonates and statins are bone protective (Walsh et al., 2012) , whereas hypercholesterolemia is associated with bone loss (Orozco, 2004; Tarakida et al., 2011) . As a loss-of-cholesterol-function approach, we treated WT or ERRaKO mice with zoledronate, which targets bone more efficiently than statins, and compared them to vehicletreated mice 4 weeks later. ELISA analysis showed that zoledronate significantly decreased the serum levels of the bone resorption marker C-terminal telopeptide fragments of the type I collagen (CTX-1) in WT mice; in contrast, this effect was completely abolished in the ERRaKO mice ( Figure 6A ). Moreover, CTX-1 was reduced to a similar extent by both cholesterol ligand depletion in the zoledronate-treated mice (À82%) and by receptor deletion in the ERRaKO mice (À80%) ( Figure 6A ). In line with these results, microCT analysis of the proximal tibiae shows that zoledronate significantly increased bone mass in WT mice but not in ERRaKO mice (Figures 6B and 6C) . Furthermore, bone histomorphometry analysis showed that zoledronate significantly reduced osteoclast surface and osteoclast number in WT mice but not in ERRaKO mice ( Figure 6D ). Serum cholesterol was reduced to a similar extent in both WT and ERRaKO mice ( Figure S7A) . Complementarily, as a gain-of-cholesterol-function approach, we fed WT or ERRaKO mice with a high-cholesterol diet (HCD) for 4 weeks and compared them to chow-diet-fed control mice. ELISA analysis showed that HCD feeding significantly elevated serum CTX-1 levels by 107% in WT mice; once again, this effect was completely abolished in the ERRaKO mice (Figure 6E ). In agreement, microCT analysis of the proximal tibiae shows that HCD feeding significantly decreased bone mass in WT mice, but not in ERRaKO mice ( Figures 6F and 6G) . Furthermore, bone histomorphometry analysis showed that HCD feeding significantly increased osteoclast surface and osteoclast number in WT mice, but not in ERRaKO mice ( Figure 6H ). In accordance with these observations, the expression of previously described ERRa target genes in osteoclast and muscle (Huss et al., 2004; Wei et al., 2010 ) was significantly increased by HCD feeding in an ERRa-dependent manner (Figures S7B and S7C) . These in vivo studies indicate that the physiological function of cholesterol and the pharmacological actions of cholesterol-lowering drugs require ERRa, further supporting the notion that cholesterol is a functional endogenous ERRa agonist.
DISCUSSION
Here we identify and characterize cholesterol as a natural ERRa ligand using an integrated strategy that combines analytical chemistry, cell biology, and animal physiology. The classic nuclear receptors are known as the receptors for steroids such as estrogen, androgen, glucocorticoid, and progesterone, which are derivatives of cholesterol. Though cholesterol is not thought of a signaling molecule, cholesterol levels affect the activity of important transcription factors such as SREBPs via SCAP (Brown and Goldstein, 1997 ). Our binding model does not exclude other sterols with modifications outside of the binding site, and therefore it is possible that other sterols can also bind ERRa. Two pieces of our data support cholesterol as the major endogenous sterol ligand. First, the unbiased affinity chromatography experiments only enriched cholesterol. Other sterols should have been enriched if they could bind to ERRa in this mixture. Second, cholesterol was the only sterol with levels that correlated with the transcriptional activity of ERRa under all cellular treatment conditions we tried ( Figure S6 ). As debates about the endogenous ligands of other nuclear receptors demonstrate, it is not possible to rule out additional ligands for ERRa, but our data provide the first evidence for cholesterol and the cholesterol biosynthetic pathway in the regulation of ERRa activity and biology. Our results show that full-length endogenous ERRa recruits PGC1 coactivators upon cholesterol addition but dissociates from PGC1 coactivators upon cholesterol depletion ( Figures   4G and 5D) , supporting a functional binding of cholesterol to ERRa in cells. Our data show that cholesterol enhances ERRa interaction with PGC1b in osteoclasts ( Figure 5D ), although the effects of cholesterol to increase ERRa interaction with PGC1a in myocytes ( Figure 4G ) were less discernible due to the limitation of statin-induced toxicity in these cells. Moreover, computational docking of cholesterol into the ERRa ligand-binding pocket, fluorescence cholesterol labeling, and site-directed mutagenesis suggest that cholesterol binds with its hydroxyl group facing into the ligand-binding pocket. Because the ligand-binding pockets of ERRa and other orphan nuclear receptors can adopt alternative conformations to bind molecules, these docking studies with the apo ligand-binding domain, although informative, should be interpreted with caution.
Previous studies indicate that ERRa functions differently in many ways from classic nuclear receptors, and our identification of cholesterol as an endogenous ERRa agonist provides mechanisms for its unique property. First, the ubiquity of cholesterol explains why ERRa is constitutively active. Second, the ability of cholesterol to recruit coactivators PGC1a/b to ERRa explains why ERRa activity is highly dependent on PGC1a/b. Third, because cholesterol is essential for cellular function, cholesterol depletion can only be partially achieved ( Figure S6) ; therefore, the effects of cholesterol depletion and cholesterol add-back on ERRa transcriptional outputs in the reporter assays were modest yet highly significant (Figure 3) . These findings reveal ERRa as a metabolic-sensing nuclear receptor and a homeostatic rheostat, distinguishing it from steroid receptors that respond to acute and steep rise in hormonal levels.
This discovery also elucidates a key mechanistic understanding for how ERRa serves as a critical metabolic and cholesterol sensor: cholesterol promotes osteoclastogenesis and myogenesis, and suppresses macrophage cytokine production, by activating its receptor ERRa; and ERRa regulates these cellular processes by responding to a rise or fall in cellular cholesterol level (Figure 7) . In macrophages, it is possible that cholesterol activation of ERRa may induce a transcriptional repressor for Cxcl9 and Cxcl10. Moreover, our findings illuminate new mechanistic insights for how clinically used drugs such as statins and bisphosphonates actually act by identifying ERRa as an essential mediator: both statin-induced muscle toxicity and bisphosphonate-induced osteoprotection result from a reduction of cholesterol synthesis and consequently decreased ERRa activity ( Figure 7) . Particularly, our results question the longstanding hypothesis that the inhibition of osteoclast activity by bisphosphonates is solely due to the blockade of protein prenylation. Our results show that receptor loss by ERRa deletion and ligand depletion by statin (Figure 4) or bisphosphonate ( Figure 6 ) led to a similar degree of serum CTX-1 reduction and serum CK induction; moreover, in the absence of the receptor ERRa, these effects by ligand depletion were completely abolished. Together, these findings suggest that the pharmacological actions of statins and bisphosphonates are ERRa dependent.
In support of a negative impact of cholesterol on bone mass, epidemiological and pharmacological studies show that cholesterol-lowering drugs such as bisphosphonates and statins are bone protective in human (Walsh et al., 2012) , whereas hypercholesterolemia is associated with bone loss (Orozco, 2004; Tarakida et al., 2011) . Rare genetic disorders of cholesterol biosynthesis, however, have been associated with higher bone density. Desmosterolosis is caused by a mutation in the gene encoding 24-dehydrocholesterol reductase, which causes a marked accumulation of desmosterol but normal or slightly reduced cholesterol (Andersson et al., 2002; FitzPatrick et al., 1998; Schaaf et al., 2011) . This is distinct from statins, which inhibit HMG CoA reductase and cause a generalized reduction in sterols including cholesterol and desmosterol. Thus, the osteosclerosis observed in one out of three desmosterolosis patients identified to date may be caused by an elevated desmosterol rather than decreased cholesterol. Antley-Bixler syndrome is caused by either mutations in the FGFR2 gene or mutations in the cytochrome p450 oxydoreductase (POR) gene. The latter results in a broad spectrum abnormality in steroidogenesis and hormonal disorders (Flü ck et al., 2004) , which may explain the craniosysnostosis phenotype.
Our conclusion of the ERRa dependency of cholesterol regulation is supported by the consistency between ERRa-KO genetic model and XCT790 ERRa antagonist chemical model. Moreover, the effects of XCT790 we observed were completely abolished in ERRa-KO cultures ( Figure S5A ), demonstrating that ERRa is the major target of XCT790 in our system. Interestingly, a recent report (Eskiocak et al., 2014) showed that XCT790 can function as a mitochondrial uncoupler independent of ERRa in a melanoma cell line using siRNA ERRa knockdown; however, this in vitro observation was highly dependent on the cell lines Cholesterol serves as a natural ERRa agonist to recruit coactivators PGC1a/b and increase ERRa transcriptional activity, thereby promoting osteoclastogenesis and myogenesis but inhibiting macrophage cytokine production. A reduction in cholesterol synthesis by statins or bisphosphonates decreases ERRa transcriptional activity, thereby mediating the statin-induced muscle toxicity and bisphosphonate suppression of bone resorption.
and thus a context-specific effect that may not be extendable to generalized physiological settings.
The impairment of cholesterol, statin, and bisphosphonate regulation in ERRa-KO mice was not due to a saturation of the phenotype. ERRa deletion or inhibition reduced baseline osteoclast and myotube differentiation, but did not completely abolish the ability to differentiate; for example, ERRa-KO osteoclast cultures indeed still showed induction of differentiation markers TRAP and Ctsk upon RANKL treatment (which is dependent on its receptor RANK and modulated by ERRa) ( Figure 5B, bottom) ; only the induction of ERRa target genes was completely abolished ( Figure 5B, top) . Moreover, previous studies from our lab and others have shown that many other genetic defects can cause much more severe osteopetrotic phenotype, with a BV/ TV ratio reaching 0.8 (Kong et al., 1999; Wei et al., 2011; Xing et al., 2013) , more than 2-fold higher than the BV/TV of $0.3 in ERRa-KO mice, indicating that the osteoclast and bone phenotype in ERRa-KO mice is by no means saturated. In addition, glucocorticoid-induced myopathy was intact in ERRa-KO, demonstrating that ERRa-KO mice remain sensitive to ERRa-independent stimuli ( Figure S7D) . Therefore, the inability of ERRa-KO cells and mice to respond to statin, bisphosphonate, and cholesterol support a specific requirement of ERRa in the regulation by the cholesterol pathway.
Interestingly, there is a crosstalk between ERRa and ERa, including recognition of the estrogen response element (ERE) by ERRa. In ER negative (ERÀ) breast cancer, the presence of ERRa is a negative prognostic factor as it compensates for the loss of ERa in addition to triggering the expression of ERa-independent genes (Suzuki et al., 2004) . Thus, the function of cholesterol as an ERRa agonist may provide molecular basis and mechanistic insight into clinical studies suggesting that statins can be used to treat or prevent ERÀ breast cancer (Cuzick et al., 2011; Kumar et al., 2008) . The presence or absence of ERRa in ERÀ breast cancer may be a prognostic factor for the effectiveness of cholesterol-lowering treatments as anticancer therapeutics. Although it remains to be seen whether it is universally effective in the clinical settings to modulate ERRa transactivation through therapeutic regulation of cholesterol, as well as to modulate cholesterol function through ERRa-targeting small molecules, the deorphanization of ERRa using a widely applicable approach opens a new frontier in nuclear receptor biology.
EXPERIMENTAL PROCEDURES
Biochemical Analyses 6xHis-ERRa-LBD plasmid was obtained courtesy of Dino Moras. 6xHis-ERRa-LBD was transformed into Rosetta cells and expressed and purified as previously described (Greschik et al., 2008) . Lipids were extracted into chloroform from brain or kidney by dounce homogenization. Global lipid pull-downs were performed as previously described , but with larger concentrations of protein and lipid. Centrifuge columns (Pierce #89868) were loaded with 10 ml IMAC sepharose 6 Fast Flow beads (GE). Beads were washed with water (2 3 500 ml) and the wash was removed by centrifugation. A total of 100 ml 0.2M nickel sulfate was added to each column, and the column was incubated for 30 min. Nickel sulfate was then eluted, and columns were washed with water (3 3 100 ml) and protein buffer (20 mM Tris, 200 mM NaCl [pH 8.0]) (3 3 200 ml). A total of 200 ml of 25 mM or 50 mM HIS-ERRa-LBD or protein buffer containing no protein was incubated with resin for 2 hr. After incubation, protein was eluted and beads were washed with protein buffer containing 50 mM imidazole (3 3 200 ml). To prepare the lipid mixture, brain lipid extracts were dissolved in DMSO at 40 ml/mg, vortexed, and then sonicated in a sonicator bath to ensure solubilization of the lipids. A total of 12% lipid mixture was prepared by adding the DMSO lipid stock to protein buffer at 12% by volume. This mixture was vortexed and sonicated in a sonicator bath, and then 100 ml was added to column and incubated for 30 min. The lipid mixture was then eluted and columns were washed with protein buffer containing 50 mM imidazole (3 3 100 ml). Protein-lipid conjugate was then eluted with protein buffer containing 250 mM imidazole (3 3 100 ml), and 80 ml were injected on Agilent 6220 LC-MS TOF in negative or positive mode. For mass spectrometry, capillary voltage was 3,500 V, and fragmentor voltage was 100 V; nebulizer gas was 45 psi; drying gas temp was 350 C with a flow of 10 L/min; m/z range was from 100 to 1,500 Daltons. This procedure was done in triplicate. Targeted sterol analysis was performed using a MRM mode on an Agilent 6140 QQQ LC-MS/MS. Docking simulations were performed using autodock vina (Trott and Olson, 2010) . Circular dichroism experiments were performed on a Jasco J-710 spectrophotometer. Tryptophan fluorescence quenching experiments and fluorescence polarization experiments were performed on a spectramax M5 spectrophotometer.
Cellular and In Vivo Analyses
Transfection and luciferase reporter assay were performed in CV-1 cells as described (Wei et al., 2010) . Bone marrow osteoclast differentiation assays and bone analyses (microCT, ELISA, and histomorphometry) were performed as described (Wei et al., 2010) . C2C12 cells were cultured in DMEM + 10% FBS and differentiated into myotubes in DMEM+2% horse serum. ERRa knockout mice on a C57BL6/J background were previously described (Luo et al., 2003; Wei et al., 2010) . Simvastatin was administered at 20 mg/kg/day for 14 days. Zoledronate was administered by a single intravenous injection at 0.54 mg/kg. HCD (2% cholesterol, 0.5% NaCholate) and normal chow diet control were from Harlan Teklad. All mouse experiments were conducted using littermates. Sample size estimate was based on power analyses performed using SAS 9.3 TS X64_7PRO platform at the UT Southwestern Biostatistics Core. With the observed group differences and the relatively small variation of the in vivo measurements, a sample size of four per group (n = 4) will provide >90% power at type I error rate of 0.05 (two-sided test), and a sample size of three per group (n = 3) will provide >80% power at type I error rate of 0.05 (two-sided test). All animal experiments were approved by the Institutional Animal Care and Use Committee of the University of Texas Southwestern Medical Center.
Statistical Analyses
All statistical analyses were performed with Student's t test and presented as mean ± SD unless stated otherwise. The p values were designated as *p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001; n.s., nonsignificant (p > 0.05).
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